1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

  • October 2015
  • 43 pages
  • GlobalData
Report ID: 3161502

Summary

Table of Contents

Search Inside

EpiCast Report: Multiple Myeloma - Epidemiology Forecast to 2023

Summary

Multiple myeloma is a hematologic cancer of the white blood cell; more specifically, multiple myeloma is a cancer of the plasma cell. Normal plasma cells help fight infections by making antibodies that recognize and attack germs, but multiple myeloma causes cancer cells to accumulate in the bone marrow where they crowd out healthy blood cells, impairing their ability to fight infections. Rather than producing helpful antibodies, the cancer cells produce abnormal proteins called monoclonal (M) proteins that can impair kidney functions.

GlobalData epidemiologists forecast the diagnosed incident and five-year diagnosed prevalent cases of multiple myeloma in the 8MM. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of multiple myeloma in the 8MM, from 67,557 diagnosed incident cases in 2013 to 97,225 diagnosed incident cases in 2023, with an Annual Growth Rate (AGR) of 4.39% during the forecast period. The five-year diagnosed prevalent cases of multiple myeloma in the 8MM are expected to increase from 168,750 diagnosed prevalent cases in 2013 to 236,866 diagnosed prevalent cases in 2023, with an AGR of 4.04% during the forecast period. The increase in the diagnosed five-year prevalent cases of multiple myeloma is partly attributed to the moderately rising trend in the incidence of multiple myeloma in the 8MM, combined with changes in the population demographics in the respective markets.

GlobalData’s forecast is supported by at least 10 years of robust, country-specific historical data obtained from the WHO International Agency for Cancer Research’s (IARC’s) SurvCan, the Surveillance of Epidemiology and End Results Program Cancer Statistics Review 1975-2009, EUROCARE-4, research articles published in peer-reviewed journals, and the IARC’s Cancer Incidence in Five Continents Plus database, which provided detailed case segmentation by age and sex and is considered the gold standard for international comparison of country-specific data. Another strength of this analysis is that GlobalData epidemiologists compared the incident case projections with the estimates made by country-specific registries and the IARC, and found that the forecast numbers were in accordance with the international estimates.

Scope

- The Multiple Myleoma EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for multiple myeloma in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and urban China). The series includes a 10-year epidemiological forecast for diagnosed incident and total prevalent cases of monoclonal gammopathy of undetermined significance (MGUS) cases, segmented by age and sex. It also includes a 10-year forecast for diagnosed incident cases of multiple myeloma, segmented by age (in five-year increments beginning at 40 years and ending at =85 years), sex, and stage at clinical diagnosis, as well as a 10-year epidemiological forecast for the five-year diagnosed prevalent cases of multiple myeloma in these markets.
- The Multiple Myeloma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to buy

The Multiple Myeloma EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global multiple myeloma market.
- Quantify patient populations in the global multiple myeloma market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the sex and age groups that present the best opportunities for multiple myeloma therapeutics in each of the markets covered.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Veronica helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Cervical Cancer Disease Coverage Forecast and Market Analysis to 2023

  • $ 22000
  • Industry report
  • June 2017
  • by Datamonitor Healthcare

Cervical cancer is a major gynecological cancer which involves uncontrolled cell division and tissue invasiveness of the female uterine cervix. Incidence rates are highest in sub-Saharan Africa, Latin ...

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

  • $ 10995
  • Industry report
  • May 2017
  • by GlobalData

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025 Summary Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death among gynecological ...

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

  • $ 6995
  • Industry report
  • May 2017
  • by GBI Research

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline Summary Hematological cance ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.